10 years in Canada and counting1
HUMIRA is indicated for:2
• Inducing and maintaining clinical remission in pediatric patients 5 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6-mercaptopurine or who are intolerant to such therapies.
• Treatment of chronic non-infectious anterior uveitis (UV) in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
• Treatment of active moderate to severe hidradenitis suppurativa (HS) in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics)
• Reducing the signs and symptoms and inducing and maintaining clinical remission in pediatric patients 13 to 17 years of age weighing ≥40 kg with severely active Crohn’s disease (CD) and/or who have had an inadequate response or were intolerant to conventional therapy (a corticosteroid and/or aminosalicylate and/or an immunosuppressant) and/or a tumour necrosis factor (TNF)-alpha antagonist.
• In combination with methotrexate, reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients, 2 years of age and older who have had an inadequate response to one or more disease-modifying antirheumatic drugs. HUMIRA can be used as monotherapy in case of intolerance to MTX or when continued treatment with MTX is not appropriate. HUMIRA has not been studied in pediatric patients with polyarticular JIA aged less than 2 years.
AbbVie is proud to be your partner in the treatment of JIA,* pedUV, pedCD, pedUC and adolescent HS.
Our pediatric indications
AbbVie: 10 years of continued dedication to pediatrics and adolescent patients and counting
Juvenile Idiopathic Arthritis (JIA)
Pediatric Uveitis (UV)
Adolescent Hidradenitis Suppurativa (HS)
AbbVie is here as your partner with
the AbbVie Care program, every
step of the way
10
More than 10 years in Canada
Trust in our experience across
4 pediatric and 1 adolescent
indications
6,000
Since 2012, over 6,000 Canadian
pediatric and adolescent patients
have been supported by the
AbbVie Care Program across 3
therapeutic areas and 5
indications
23,000
Over 23,000 pediatric and
adolescent patients
worldwide were treated with
HUMIRA in 2021
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma, serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic DMARDs or other TNF antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-888-704-8271.
* Polyarticular JIA
References
1. AbbVie Corporation. Data on File.
2. HUMIRA Product Monograph. AbbVie Corporation.
CA-HUMR-220010A / NO23